Elevated programmed cell death-1 protein/ligand (PD-1/PD-L1) and variants are associated with susceptibility to multiple myeloma: a case-control study in the Chinese cohort

References

• Rosenblatt, J.; Bar-Natan, M.; Munshi, N. C.; Avigan, D. E. Immunotherapy for Multiple Myeloma. Expert Rev. Hematol. 2014, 7, 91–96. DOI: 10.1586/17474086.2014.878226.
   PubMed Web of Science ®Google Scholar
• Dosani, T.; Carlsten, M.; Maric, I.; Landgren, O. The Cellular Immune System in Myelomagenesis: NK Cells and T Cells in the Development of Myeloma [Corrected] and Their Uses in Immunotherapies. Blood Cancer J. 2015, 5, e306–e306. DOI: 10.1038/bcj.2015.32.
   PubMed Web of Science ®Google Scholar
• Cowan, A. J.; Green, D. J.; Kwok, M.; Lee, S.; Coffey, D. G.; Holmberg, L. A.; Tuazon, S.; Gopal, A. K.; Libby, E. N. Diagnosis and Management of Multiple Myeloma: A Review. Jama 2022, 327, 464–477. DOI: 10.1001/jama.2022.0003.
   PubMed Web of Science ®Google Scholar
• Munshi, N. C.; Wilson, C. Increased Bone Marrow Microvessel Density in Newly Diagnosed Multiple Myeloma Carries a Poor Prognosis. Semin. Oncol. 2001, 28, 565–569. DOI: 10.1053/sonc.2001.28954.
   PubMed Web of Science ®Google Scholar
• Vacca, A.; Ribatti, D.; Roccaro, A. M.; Frigeri, A.; Dammacco, F. Bone Marrow Angiogenesis in Patients with Active Multiple Myeloma. Semin. Oncol. 2001, 28, 543–550. DOI: 10.1053/sonc.2001.28604.
   PubMed Web of Science ®Google Scholar
• Palumbo, A.; Anderson, K. Multiple Myeloma. N Engl. J. Med. 2011, 364, 1046–1060. DOI: 10.1056/NEJMra1011442.
   PubMed Web of Science ®Google Scholar
• Guedes, A.; Becker, R. G.; Teixeira, L. E. M. Multiple Myeloma (Part 1) - Update on Epidemiology, Diagnostic Criteria, Systemic Treatment and Prognosis. Rev. Bras. Ortop. (Sao Paulo) 2023, 58, 361–367. DOI: 10.1055/s-0043-1770149.
   PubMedGoogle Scholar
• Keir, M. E.; Butte, M. J.; Freeman, G. J.; Sharpe, A. H. PD-1 and Its Ligands in Tolerance and Immunity. Annu. Rev. Immunol. 2008, 26, 677–704. DOI: 10.1146/annurev.immunol.26.021607.090331.
   PubMed Web of Science ®Google Scholar
• Polanczyk, M. J.; Hopke, C.; Vandenbark, A. A.; Offner, H. Estrogen-Mediated Immunomodulation Involves Reduced Activation of Effector T Cells, Potentiation of Treg Cells, and Enhanced Expression of the PD-1 Costimulatory Pathway. J. Neurosci. Res. 2006, 84, 370–378. DOI: 10.1002/jnr.20881.
   PubMed Web of Science ®Google Scholar
• Dong, H.; Strome, S. E.; Salomao, D. R.; Tamura, H.; Hirano, F.; Flies, D. B.; Roche, P. C.; Lu, J.; Zhu, G.; Tamada, K.; et al. Tumor-Associated B7-H1 Promotes T-Cell Apoptosis: A Potential Mechanism of Immune Evasion. Nat. Med. 2002, 8, 793–800. DOI: 10.1038/nm730.
   PubMed Web of Science ®Google Scholar
• Iwai, Y.; Ishida, M.; Tanaka, Y.; Okazaki, T.; Honjo, T.; Minato, N. Involvement of PD-L1 on Tumor Cells in the Escape from Host Immune System and Tumor Immunotherapy by PD-L1 Blockade. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 12293–12297. DOI: 10.1073/pnas.192461099.
   PubMed Web of Science ®Google Scholar
• Jang, Y. S.; Kim, T. W.; Ryu, J. S.; Kong, H. J.; Jang, S. H.; Nam, G. H.; Kim, J. H.; Jeon, S. Upregulation of Programmed Death Ligand-1 in Tumor-Associated Macrophages Affects Chemotherapeutic Response in Ovarian Cancer Cells. PLoS One 2023, 18, e0277285. DOI: 10.1371/journal.pone.0277285.
   PubMed Web of Science ®Google Scholar
• Zhang, P.; Ouyang, S.; Wang, J.; Huang, Z.; Wang, J.; Liao, L. [Levels of Programmed Death-1 and Programmed Death Ligand-1 in the Peripheral Blood of Patients with Oral Squamous Cell Carcinoma and Its Clinical Implications]. Hua Xi Kou Qiang Yi Xue Za Zhi 2015, 33, 529–533.
   PubMedGoogle Scholar
• Nagato, T.; Ohkuri, T.; Ohara, K.; Hirata, Y.; Kishibe, K.; Komabayashi, Y.; Ueda, S.; Takahara, M.; Kumai, T.; Ishibashi, K.; et al. Programmed Death-Ligand 1 and Its Soluble Form Are Highly Expressed in Nasal Natural Killer/T-Cell Lymphoma: A Potential Rationale for Immunotherapy. Cancer Immunol. Immunother. 2017, 66, 877–890. DOI: 10.1007/s00262-017-1987-x.
   PubMed Web of Science ®Google Scholar
• Baptista, M. Z.; Sarian, L. O.; Derchain, S. F.; Pinto, G. A.; Vassallo, J. Prognostic Significance of PD-L1 and PD-L2 in Breast Cancer. Hum. Pathol. 2016, 47, 78–84. DOI: 10.1016/j.humpath.2015.09.006.
   PubMed Web of Science ®Google Scholar
• Yang, C. Y.; Lin, M. W.; Chang, Y. L.; Wu, C. T.; Yang, P. C. Programmed Cell Death-Ligand 1 Expression in Surgically Resected Stage I Pulmonary Adenocarcinoma and Its Correlation with Driver Mutations and Clinical Outcomes. Eur. J. Cancer 2014, 50, 1361–1369. DOI: 10.1016/j.ejca.2014.01.018.
   PubMed Web of Science ®Google Scholar
• Fest, T.; Rossille, D.; Gressier, M.; Maucort-Boulch, D.; Damotte, D.; Pangault, C.; Le Gouill, S.; Tarte, K.; Lamy, T.; Milpied, N. Blood Soluble PD-L1 Protein in Aggressive Diffuse Large B-Cell Lymphoma Impacts Patient’s Overall Survival. Blood 2013, 122, 361–361. DOI: 10.1182/blood.V122.21.361.361.
   Google Scholar
• Taube, J. M.; Anders, R. A.; Young, G. D.; Xu, H.; Sharma, R.; McMiller, T. L.; Chen, S.; Klein, A. P.; Pardoll, D. M.; Topalian, S. L.; Chen, L. Colocalization of Inflammatory Response with B7-h1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. Sci. Transl. Med. 2012, 4, 127ra37. DOI: 10.1126/scitranslmed.3003689.
   PubMed Web of Science ®Google Scholar
• Sorensen, S. F.; Zhou, W.; Dolled-Filhart, M.; Georgsen, J. B.; Wang, Z.; Emancipator, K.; Wu, D.; Busch-Sorensen, M.; Meldgaard, P.; Hager, H. PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy. Transl. Oncol. 2016, 9, 64–69. DOI: 10.1016/j.tranon.2016.01.003.
   PubMed Web of Science ®Google Scholar
• Cheng, H.-Y.; Kang, P.-J.; Chuang, Y.-H.; Wang, Y.-H.; Jan, M.-C.; Wu, C.-F.; Lin, C.-L.; Liu, C.-J.; Liaw, Y.-F.; Lin, S.-M.; et al. Circulating Programmed Death-1 as a Marker for Sustained High Hepatitis B Viral Load and Risk of Hepatocellular Carcinoma. PLoS One 2014, 9, e95870. DOI: 10.1371/journal.pone.0095870.
   PubMed Web of Science ®Google Scholar
• Zou, J.; Wu, D.; Li, T.; Wang, X.; Liu, Y.; Tan, S. Association of PD-L1 Gene rs4143815 C>G Polymorphism and Human Cancer Susceptibility: A Systematic Review and Meta-Analysis. Pathol. Res. Pract. 2019, 215, 229–234. DOI: 10.1016/j.prp.2018.12.002.
   PubMed Web of Science ®Google Scholar
• Dong, W.; Gong, M.; Shi, Z.; Xiao, J.; Zhang, J.; Peng, J. Programmed Cell Death-1 Polymorphisms Decrease the Cancer Risk: A Meta-Analysis Involving Twelve Case-Control Studies. PLoS One 2016, 11, e0152448. DOI: 10.1371/journal.pone.0152448.
   PubMed Web of Science ®Google Scholar
• Wang, W.; Li, F.; Mao, Y.; Zhou, H.; Sun, J.; Li, R.; Liu, C.; Chen, W.; Hua, D.; Zhang, X. A miR-570 Binding Site Polymorphism in the B7-H1 Gene is Associated with the Risk of Gastric Adenocarcinoma. Hum. Genet. 2013, 132, 641–648. DOI: 10.1007/s00439-013-1275-6.
   PubMed Web of Science ®Google Scholar
• Salmaninejad, A.; Khoramshahi, V.; Azani, A.; Soltaninejad, E.; Aslani, S.; Zamani, M. R.; Zal, M.; Nesaei, A.; Hosseini, S. M. PD-1 and Cancer: Molecular Mechanisms and Polymorphisms. Immunogenetics 2018, 70, 73–86. DOI: 10.1007/s00251-017-1015-5.
   PubMed Web of Science ®Google Scholar
• Cevik, M.; Namal, E.; Iner-Koksal, U.; Dinc-Sener, N.; Karaalp, A.; Ciftci, C.; Susleyici, B. Association of PD-1 and PDL-1 Gene Polymorphisms with Colorectal Cancer Risk and Prognosis. Mol. Biol. Rep. 2022, 49, 1827–1836. DOI: 10.1007/s11033-021-06992-9.
   PubMed Web of Science ®Google Scholar
• Greipp, P. R.; San Miguel, J.; Durie, B. G.; Crowley, J. J.; Barlogie, B.; Blade, J.; Boccadoro, M.; Child, J. A.; Avet-Loiseau, H.; Kyle, R. A.; et al. International Staging System for Multiple Myeloma. J. Clin. Oncol. 2005, 23, 3412–3420. DOI: 10.1200/JCO.2005.04.242.
   PubMed Web of Science ®Google Scholar
• Durie, B. G.; Harousseau, J. L.; Miguel, J. S.; Blade, J.; Barlogie, B.; Anderson, K.; Gertz, M.; Dimopoulos, M.; Westin, J.; Sonneveld, P.; et al. International Uniform Response Criteria for Multiple Myeloma. Leukemia 2006, 20, 1467–1473. DOI: 10.1038/sj.leu.2404284.
   PubMed Web of Science ®Google Scholar
• Xie, Q.; Chen, Z.; Xia, L.; Zhao, Q.; Yu, H.; Yang, Z. Correlations of PD-L1 Gene Polymorphisms with Susceptibility and Prognosis in Hepatocellular Carcinoma in a Chinese Han Population. Gene 2018, 674, 188–194. DOI: 10.1016/j.gene.2018.06.069.
   PubMed Web of Science ®Google Scholar
• Savabkar, S.; Azimzadeh, P.; Chaleshi, V.; Nazemalhosseini Mojarad, E.; Aghdaei, H. A. Programmed Death-1 Gene Polymorphism (PD-1.5 C/T) is Associated with Gastric Cancer. Gastroenterol. Hepatol. Bed. Bench 2013, 6, 178–182.
   PubMedGoogle Scholar
• Liu, X.; Hu, L. H.; Li, Y. R.; Chen, F. H.; Ning, Y.; Yao, Q. F. Programmed Cell Death 1 Gene Polymorphisms is Associated with Ankylosing Spondylitis in Chinese Han Population. Rheumatol. Int. 2011, 31, 209–213. DOI: 10.1007/s00296-009-1264-1.
   PubMed Web of Science ®Google Scholar
• Hua, Z.; Li, D.; Xiang, G.; Xu, F.; Jie, G.; Fu, Z.; Jie, Z.; Da, P.; Li, D. PD-1 Polymorphisms Are Associated with Sporadic Breast Cancer in Chinese Han Population of Northeast China. Breast Cancer Res. Treat. 2011, 129, 195–201. DOI: 10.1007/s10549-011-1440-3.
   PubMed Web of Science ®Google Scholar
• Panda, A. K.; Sahoo, P. K.; Kerketta, A. S.; Kar, S. K.; Ravindran, B.; Satapathy, A. K. Human Lymphatic Filariasis: Genetic Polymorphism of Endothelin-1 and Tumor Necrosis Factor Receptor II Correlates with Development of Chronic Disease. J. Infect. Dis. 2011, 204, 315–322. DOI: 10.1093/infdis/jir258.
   PubMed Web of Science ®Google Scholar
• Droeser, R. A.; Hirt, C.; Viehl, C. T.; Frey, D. M.; Nebiker, C.; Huber, X.; Zlobec, I.; Eppenberger-Castori, S.; Tzankov, A.; Rosso, R.; et al. Clinical Impact of Programmed Cell Death Ligand 1 Expression in Colorectal Cancer. Eur. J. Cancer 2013, 49, 2233–2242. DOI: 10.1016/j.ejca.2013.02.015.
   PubMed Web of Science ®Google Scholar
• Duraiswamy, J.; Freeman, G. J.; Coukos, G. Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer. Cancer Res. 2013, 73, 6900–6912. DOI: 10.1158/0008-5472.CAN-13-1550.
   PubMed Web of Science ®Google Scholar
• Ghebeh, H.; Mohammed, S.; Al-Omair, A.; Qattan, A.; Lehe, C.; Al-Qudaihi, G.; Elkum, N.; Alshabanah, M.; Bin Amer, S.; Tulbah, A.; et al. The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic Factors. Neoplasia 2006, 8, 190–198. DOI: 10.1593/neo.05733.
   PubMed Web of Science ®Google Scholar
• Wu, C.; Zhu, Y.; Jiang, J.; Zhao, J.; Zhang, X. G.; Xu, N. Immunohistochemical Localization of Programmed Death-1 Ligand-1 (PD-L1) in Gastric Carcinoma and Its Clinical Significance. Acta Histochem. 2006, 108, 19–24. DOI: 10.1016/j.acthis.2006.01.003.
   PubMed Web of Science ®Google Scholar
• Wang, L.; Wang, H.; Chen, H.; Wang, W. D.; Chen, X. Q.; Geng, Q. R.; Xia, Z. J.; Lu, Y. Serum Levels of Soluble Programmed Death Ligand 1 Predict Treatment Response and Progression Free Survival in Multiple Myeloma. Oncotarget 2015, 6, 41228–41236. DOI: 10.18632/oncotarget.5682.
   PubMedGoogle Scholar
• Wu, Y.; Ju, Q.; Qian, B.; Zhang, F.; Shi, H. The Effectiveness of PD-1 Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Patients of Different Ages. Oncotarget 2018, 9, 7942–7948. DOI: 10.18632/oncotarget.23678.
   PubMedGoogle Scholar
• Maruse, Y.; Kawano, S.; Jinno, T.; Matsubara, R.; Goto, Y.; Kaneko, N.; Sakamoto, T.; Hashiguchi, Y.; Moriyama, M.; Toyoshima, T.; et al. Significant Association of Increased PD-L1 and PD-1 Expression with Nodal Metastasis and a Poor Prognosis in Oral Squamous Cell Carcinoma. Int. J. Oral Maxillofac. Surg. 2018, 47, 836–845. DOI: 10.1016/j.ijom.2018.01.004.
   PubMed Web of Science ®Google Scholar
• Kim, H. D.; Song, G. W.; Park, S.; Jung, M. K.; Kim, M. H.; Kang, H. J.; Yoo, C.; Yi, K.; Kim, K. H.; Eo, S.; et al. Association between Expression Level of PD1 by Tumor-Infiltrating CD8(+) T Cells and Features of Hepatocellular Carcinoma. Gastroenterology 2018, 155, 1936–1950 e1917. DOI: 10.1053/j.gastro.2018.08.030.
   PubMed Web of Science ®Google Scholar
• Karim, R.; Jordanova, E. S.; Piersma, S. J.; Kenter, G. G.; Chen, L.; Boer, J. M.; Melief, C. J.; van der Burg, S. H. Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma. Clin. Cancer Res. 2009, 15, 6341–6347. DOI: 10.1158/1078-0432.CCR-09-1652.
   PubMed Web of Science ®Google Scholar
• Komura, T.; Sakai, Y.; Harada, K.; Kawaguchi, K.; Takabatake, H.; Kitagawa, H.; Wada, T.; Honda, M.; Ohta, T.; Nakanuma, Y.; et al. Inflammatory Features of Pancreatic Cancer Highlighted by Monocytes/Macrophages and CD4+ T Cells with Clinical Impact. Cancer Sci. 2015, 106, 672–686. DOI: 10.1111/cas.12663.
   PubMed Web of Science ®Google Scholar
• Maine, C. J.; Aziz, N. H.; Chatterjee, J.; Hayford, C.; Brewig, N.; Whilding, L.; George, A. J.; Ghaem-Maghami, S. Programmed Death Ligand-1 over-Expression Correlates with Malignancy and Contributes to Immune Regulation in Ovarian Cancer. Cancer Immunol. Immunother. 2014, 63, 215–224. DOI: 10.1007/s00262-013-1503-x.
   PubMed Web of Science ®Google Scholar
• Rosenblatt, J.; Glotzbecker, B.; Mills, H.; Vasir, B.; Tzachanis, D.; Levine, J. D.; Joyce, R. M.; Wellenstein, K.; Keefe, W.; Schickler, M.; et al. PD-1 Blockade by CT-011, anti-PD-1 Antibody, Enhances Ex Vivo T-Cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine. J. Immunother. 2011, 34, 409–418. DOI: 10.1097/CJI.0b013e31821ca6ce.
   PubMed Web of Science ®Google Scholar
• Paiva, B.; Azpilikueta, A.; Puig, N.; Ocio, E. M.; Sharma, R.; Oyajobi, B. O.; Labiano, S.; San-Segundo, L.; Rodriguez, A.; Aires-Mejia, I.; et al. PD-L1/PD-1 Presence in the Tumor Microenvironment and Activity of PD-1 Blockade in Multiple Myeloma. Leukemia 2015, 29, 2110–2113. DOI: 10.1038/leu.2015.79.
   PubMed Web of Science ®Google Scholar
• Tan, D.; Sheng, L.; Yi, Q. H. Correlation of PD-1/PD-L1 Polymorphisms and Expressions with Clinicopathologic Features and Prognosis of Ovarian Cancer. Cancer Biomark. 2018, 21, 287–297. DOI: 10.3233/CBM-170357.
   PubMed Web of Science ®Google Scholar
• Tao, L. H.; Zhou, X. R.; Li, F. C.; Chen, Q.; Meng, F. Y.; Mao, Y.; Li, R.; Hua, D.; Zhang, H. J.; Wang, W. P.; et al. A Polymorphism in the Promoter Region of PD-L1 Serves as a Binding-Site for SP1 and is Associated with PD-L1 Overexpression and Increased Occurrence of Gastric Cancer. Cancer Immunol. Immunother. 2017, 66, 309–318. DOI: 10.1007/s00262-016-1936-0.
   PubMed Web of Science ®Google Scholar
• Yeo, M. K.; Choi, S. Y.; Seong, I. O.; Suh, K. S.; Kim, J. M.; Kim, K. H. Association of PD-L1 Expression and PD-L1 Gene Polymorphism with Poor Prognosis in Lung Adenocarcinoma and Squamous Cell Carcinoma. Hum. Pathol. 2017, 68, 103–111. DOI: 10.1016/j.humpath.2017.08.016.
   PubMed Web of Science ®Google Scholar
• Majewski, J.; Ott, J. Distribution and Characterization of Regulatory Elements in the Human Genome. Genome Res. 2002, 12, 1827–1836. DOI: 10.1101/gr.606402.
   PubMed Web of Science ®Google Scholar
• Gazave, E.; Marques-Bonet, T.; Fernando, O.; Charlesworth, B.; Navarro, A. Patterns and Rates of Intron Divergence between Humans and Chimpanzees. Genome Biol. 2007, 8, R21. DOI: 10.1186/gb-2007-8-2-r21.
   PubMed Web of Science ®Google Scholar